Company Description
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on unmet needs in oncology by developing differentiated and novel therapeutic candidates.
Its lead product candidate is taletrectinib, an ROS1 inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer; Safusidenib, a novel, oral, potent, brain penetrant, targeted inhibitor of mutant isocitrate dehydrogenase 1 in phase 2 clinical trials; NUV-1511, a drug-drug conjugate for use in chemotherapy agent that suppresses the growth of various advanced solid tumors; NUV-868, a binding domain 2 selective, oral, small molecule bromodomain and extra-terminal inhibitor that inhibits bromodomain-containing protein 4.
The company was founded in 2018 and is headquartered in New York, New York.
| Country | United States |
| Founded | 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 220 |
| CEO | David Hung |
Contact Details
Address: 1500 Broadway, Suite 1401 New York, New York 10036 United States | |
| Phone | 332 208 6102 |
| Website | nuvationbio.com |
Stock Details
| Ticker Symbol | NUVB |
| Exchange | NYSE |
| Stock Type | Common Stock |
| Share Class | Class A Shares |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001811063 |
| CUSIP Number | 67080N101 |
| ISIN Number | US67080N1019 |
| Employer ID | 85-0862255 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. David T. Hung M.D. | Founder, President, Chief Executive Officer and Chairman |
| Dr. Gary Hattersley Ph.D. | Chief Scientific Officer |
| Dr. David Liu M.D., Ph.D. | Chief Medical Officer |
| Philippe Sauvage | Chief Financial Officer and Principal Financial Officer |
| Moses Makunje CPA | Vice President of Finance and Principal Accounting and Financial Officer |
| Stephen Dang | Vice President of Legal and Secretary |
| Stacy Markel | Chief People Officer |
| Dr. David C. Hanley Ph.D. | Chief Technical Operations Officer |
| Kerry A. Wentworth | Chief Regulatory Officer |
| Colleen Sjogren | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 25, 2025 | 8-K | Current Report |
| Mar 6, 2025 | S-3ASR | Automatic shelf registration statement of securities of well-known seasoned issuers |
| Mar 6, 2025 | 10-K | Annual Report |
| Mar 6, 2025 | 8-K | Current Report |
| Mar 5, 2025 | 8-K | Current Report |
| Mar 4, 2025 | 8-K | Current Report |
| Feb 12, 2025 | 8-K | Current Report |
| Feb 12, 2025 | SCHEDULE 13G/A | Filing |
| Dec 6, 2024 | SCHEDULE 13G/A | Filing |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |